Paris (France) – May 25th 2021
We are pleased to let you know that Keensight Capital, one of the leading European Growth Buyout firms focusing on Technology and Healthcare will acquire a majority stake in Symeres. This will facilitate our existing strategic plans to build upon what we have created at Symeres over the last 30 years including the growth and M&A strategy pursued with Gilde Healthcare since 2017. It is our ambition to be the best, most innovative, European mid-sized, integrated drug discovery and development company from hit finding to clinical proof-of-concept. With Keensight Capital’s investment, we plan to further extend and expand our range of drug discovery and development services. We believe that Keensight’s sector expertise and global reach will be a great asset to the company’s development. We are certain that our combined efforts will lead to an unmatched offering for our clients in the pharmaceutical and biotechnology industries.
For the full press release, click here.
